Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Olmesartan Medoxomil

FDA-approved product (tablet, oral), marketed as Benicar, Olmesartan Medoxomil.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Olmesartan Medoxomil
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Cardiovascular disease
  • Diabetes mellitus
  • Heart failure
  • Hypertension
  • Myocardial infarction
  • Stroke

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Angiotensin ii receptor blockers (arbs), plain
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA, E. coli and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA49.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli42.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae26.2% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis55.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Olmesartan Medoxomil in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Olmesartan Medoxomil with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Olmesartan on Ambulatory Blood Pressure Change

    NCT00854763 · start 2009-04

    Registered record
    Registry ID
    NCT00854763
    Conditions
    Hypertension
    Interventions
    olmesartan
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Unknown
    Start
    2009-04
    Completion
    Not recorded
    Enrolment
    100

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHypertension
    Interventionolmesartan
    PhaseNot recorded
    Registry statusUnknown

  • Effect of Two Doses of Olmesartan Medoxomil and Amlodipine on Vascular Markers in Hypertensive Patients With Metabolic Syndrome

    NCT00891267 · start 2008-10

    Registered record
    Registry ID
    NCT00891267
    Conditions
    Metabolic Syndrome; Hypertension
    Interventions
    Olmesartan medoxomil tablets low dose; Olmesartan medoxomil tablets high dose; Amlodipine
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2008-10
    Completion
    2011-05
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMetabolic Syndrome; Hypertension
    InterventionOlmesartan medoxomil tablets low dose; Olmesartan medoxomil tablets high dose; Amlodipine
    PhasePhase 3
    Registry statusCompleted

  • Prognostic Value of the Circadian Pattern of Ambulatory Blood Pressure for Multiple Risk Assessment

    NCT00741585 · start 2008-09-01

    Registered record
    Registry ID
    NCT00741585
    Conditions
    Essential Hypertension; Cardiovascular Disease; Stroke; Chronic Kidney Disease
    Interventions
    Any antihypertensive medication alone or in combination; Any antihypertensive medication alone or in combination; Ambulatory blood pressure monitoring
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2008-09-01
    Completion
    2018-06-30
    Enrolment
    21,983

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEssential Hypertension; Cardiovascular Disease; Stroke; Chronic Kidney Disease
    InterventionAny antihypertensive medication alone or in combination; Any antihypertensive medication alone or in combination; Ambulatory blood pressure monitoring
    PhasePhase 4
    Registry statusCompleted

  • Olmesartan/HCTZ 40/12.5 mg Combination Therapy Versus Olmesartan Medoxomil 40 mg Monotherapy in Essential Hypertension

    NCT00441350 · start 2007-07

    Registered record
    Registry ID
    NCT00441350
    Conditions
    Hypertension
    Interventions
    OM 40; OM/HCTZ 40/12.5
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2007-07
    Completion
    2008-05
    Enrolment
    1,004

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHypertension
    InterventionOM 40; OM/HCTZ 40/12.5
    PhasePhase 3
    Registry statusCompleted

  • Post-Marketing Surveillance Of Olmesartan Medoxomil In Combination With Hydrochlorothiazide

    NCT00796159 · start 2007-07

    Registered record
    Registry ID
    NCT00796159
    Conditions
    Hypertension
    Interventions
    Olmesartan medoxomil
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2007-07
    Completion
    2008-12
    Enrolment
    1,723

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHypertension
    InterventionOlmesartan medoxomil
    PhaseNot recorded
    Registry statusCompleted

  • Assessment of the Effectiveness of OLMETEC® and OLMETEC PLUS® for Treatment of Hypertension in Stage I and II Patients (Study P05254)(COMPLETED)

    NCT00811226 · start 2007-04

    Registered record
    Registry ID
    NCT00811226
    Conditions
    Hypertension
    Interventions
    olmesartan medoxomile alone or combined with hydrochlorothiazide,
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2007-04
    Completion
    2008-01
    Enrolment
    450

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHypertension
    Interventionolmesartan medoxomile alone or combined with hydrochlorothiazide,
    PhaseNot recorded
    Registry statusCompleted

  • A Study of the Blood Pressure Lowering Ability and Safety of Olmesartan Medoxomil in Stage I and Stage II Hypertension

    NCT00430638 · start 2006-12

    Registered record
    Registry ID
    NCT00430638
    Conditions
    Hypertension
    Interventions
    olmesartan medoxomil + hydrochlorothiazide, if necessary; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2006-12
    Completion
    2007-10
    Enrolment
    278

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHypertension
    Interventionolmesartan medoxomil + hydrochlorothiazide, if necessary; Placebo
    PhasePhase 4
    Registry statusCompleted

  • Fasting Study of Olmesartan Medoxomil and Hydrochlorothiazide Tablets 40 mg/25 mg and Benicar HCT® Tablets 40 mg/25 mg

    NCT01020214 · start 2006-11

    Registered record
    Registry ID
    NCT01020214
    Conditions
    Healthy
    Interventions
    Olmesartan Medoxomil and Hydrochlorothiazide Tablets 40 mg/25 mg; Benicar HCT® Tablets 40 mg/25 mg
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2006-11
    Completion
    2006-11
    Enrolment
    36

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionOlmesartan Medoxomil and Hydrochlorothiazide Tablets 40 mg/25 mg; Benicar HCT® Tablets 40 mg/25 mg
    PhasePhase 1
    Registry statusCompleted

  • Efficacy and Safety of Olmesartan Medoxomil in Stage 1 and 2 Essential Hypertension

    NCT00890591 · start 2006-08

    Registered record
    Registry ID
    NCT00890591
    Conditions
    Essential Hypertension
    Interventions
    olmesartan medoxomil + hydrochlorothiazide, if necessary + amlodipine, if necessary
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2006-08
    Completion
    2007-08
    Enrolment
    144

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEssential Hypertension
    Interventionolmesartan medoxomil + hydrochlorothiazide, if necessary + amlodipine, if necessary
    PhasePhase 4
    Registry statusCompleted

  • The Japan-Combined Treatment With Olmesartan and a Calcium Channel Blocker Versus Olmesartan and Diuretics Randomized Efficacy Study (J-CORE)

    NCT00607035 · start 2006-05

    Registered record
    Registry ID
    NCT00607035
    Conditions
    Hypertension
    Interventions
    Olmesartan medoxomil ＋Azelnidipine; Olmesartan medoxomil + Hydrochlorothiazide
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2006-05
    Completion
    2008-05
    Enrolment
    220

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHypertension
    InterventionOlmesartan medoxomil ＋Azelnidipine; Olmesartan medoxomil + Hydrochlorothiazide
    PhasePhase 4
    Registry statusCompleted

  • Olmesartan and an add-on Treatment in Patients With Mild to Moderate Hypertension

    NCT00311155 · start 2006-03

    Registered record
    Registry ID
    NCT00311155
    Conditions
    Essential Hypertension
    Interventions
    olmesartan medoxomil + hydrochlorothiazide, if necessary + amlodipine, if necessary
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2006-03
    Completion
    2008-04
    Enrolment
    694

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEssential Hypertension
    Interventionolmesartan medoxomil + hydrochlorothiazide, if necessary + amlodipine, if necessary
    PhasePhase 4
    Registry statusCompleted

  • Fed Study of Olmesartan Medoxomil Tablets 40 mg and Benicar® Tablets 40 mg

    NCT00648219 · start 2005-12

    Registered record
    Registry ID
    NCT00648219
    Conditions
    Healthy
    Interventions
    Olmesartan Medoxomil Tablets 40 mg; Benicar® Tablets 40 mg
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2005-12
    Completion
    2006-01
    Enrolment
    36

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionOlmesartan Medoxomil Tablets 40 mg; Benicar® Tablets 40 mg
    PhasePhase 1
    Registry statusCompleted

  • Fasting Study of Olmesartan Medoxomil Tablets 40 mg and Benicar® Tablets 40 mg

    NCT00649623 · start 2005-12

    Registered record
    Registry ID
    NCT00649623
    Conditions
    Healthy
    Interventions
    Olmesartan Medoxomil Tablets 40 mg; Benicar® Tablets 40 mg
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2005-12
    Completion
    2005-12
    Enrolment
    36

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionOlmesartan Medoxomil Tablets 40 mg; Benicar® Tablets 40 mg
    PhasePhase 1
    Registry statusCompleted

  • Renin Profiling in Selection of Initial Antihypertensive Drug

    NCT00834600 · start 2005-12

    Registered record
    Registry ID
    NCT00834600
    Conditions
    Hypertension
    Interventions
    olmesartan, hydrochlorothiazide, amlodipine; hydrochlorothiazide (HCTZ) or olmesartan
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2005-12
    Completion
    2011-10
    Enrolment
    185

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHypertension
    Interventionolmesartan, hydrochlorothiazide, amlodipine; hydrochlorothiazide (HCTZ) or olmesartan
    PhaseNot applicable
    Registry statusCompleted

  • Trial to Investigate the Efficacy of Olmesartan in Paroxysmal Atrial Fibrillation

    NCT00098137 · start 2005-01

    Registered record
    Registry ID
    NCT00098137
    Conditions
    Heart Disease; Arrhythmia; Atrial Fibrillation
    Interventions
    Olmesartan
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2005-01
    Completion
    2009-05
    Enrolment
    422

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHeart Disease; Arrhythmia; Atrial Fibrillation
    InterventionOlmesartan
    PhasePhase 3
    Registry statusCompleted